摘要
目的探讨紫杉醇联合顺铂(TP方案)同步放化疗治疗中晚期宫颈癌的临床疗效及安全性。方法 97例中晚期宫颈癌患者,按随机数字表法分为TP方案同步放化疗组(48例)与单纯放疗组(49例),分别给予TP方案和单纯放疗,观察两组临床疗效和不良反应发生情况。结果 TP方案同步放化疗组与单纯放疗组治疗总有效率分别为83.3%和53.0%,差异有统计学意义(P<0.05);TP方案同步放化疗组3年生存率显著高于单纯放疗组(75.6%vs 53.7%,P<0.05);不良反应发生率亦高于单纯放疗组(P<0.05),但患者均能耐受。结论与单纯放疗相比,TP方案同步放化疗治疗中晚期宫颈癌可显著提高患者近期疗效及3年生存率,改善预后。
Objective To compare the clinical efficacy of paclitaxel plus cisplatin （TP）concurrent chemo-radiotherapy with that of simple radiotherapy in treatment of advanced cervical cancer. Methods Ninety-seven patients with advanced cervical cancer were assigned into chemo-radiotherapy group（ N = 48 ）and simple radiotherapy group（ N = 49）by using a random number table, then were treated with TP regiment and simple radiotherapy respectiuely, the clinical efficacy and adverse effects were observed. Results The total effective rate of the concurrent chemo-radiotherapy group and the simple radiotherapy group was 83.3% and 53.0% , respec- tively. The difference was statistically significant （ P 〈 0. 05 ）. The 3-year overall survival rate in the concurrent chemo-radiotherapy group was significantly higher than that in the simple radiotherapy group（75.6% vs. 53.7 % ,P 〈 0. 05）. However,incidence of ad- verse reactions in the ehemo-radiotherapy group was also significantly higher than that in the simple radiotherapy group （ P 〈 0. 05 ）. However, the adverse reactions were tolerable by the patients. Conclusion Compared with simple radiotherapy, TP concurrent chemo- radiotherapy can dramatically improve the short-term curative effect,3 year-survival rate and prognosis.
出处
《实用医院临床杂志》
2014年第6期167-169,共3页
Practical Journal of Clinical Medicine
关键词
TP方案
同步放化疗
中晚期宫颈癌
紫杉醇
顺铂
TP program, Concurrent chemo-radiotherapy
Advanced cervical cancer
Paclitaxel
DDP
